TY - JOUR
T1 - Performance characteristics of four immunoassays for antiepileptic drugs on the IMMULITE 2000 automated analyzer
AU - Frank, Elizabeth L.
AU - Schwarz, Elisabeth L.
AU - Juenke, Jo Etta
AU - Annesley, Thomas M.
AU - Roberts, William L.
N1 - Generated from Scopus record by KAUST IRTS on 2023-09-20
PY - 2002/7/17
Y1 - 2002/7/17
N2 - Carbamazepine, phenobarbital, phenytoin, and valproic acid are commonly used antiepileptic drugs that show complicated pharmacokinetic behavior. Nonisotopic immunoassays are used routinely to monitor these drugs, and assay specificity is important to obtain accurate results. By using samples from subjects receiving each of these antiepileptic medications, competitive immunoassays for them were evaluated on an IMMULITE 2000 automated chemiluminescent analyzer (Diagnostic Products, Los Angeles, CA). Phenytoin assays were evaluated using an additional set of samples from patients with abnormal renal function. All 4 methods were linear, had imprecision of less than 10%, and compared well with other commercial immunoassays. A positive bias was observed for phenytoin measured in samples from uremic patients compared with a high-performance liquid chromatography reference method. The molar cross- reactivity of carbamazepine-10,11-epoxide was 12% in the carbamazepine assay. Phenytoin metabolites and fosphenytoin had substantial cross-reactivity in the phenytoin assay. All antiepileptic drug assays performed well and are suitable for use in monitoring patients receiving antiepileptic drug therapy. One possible exception is the phenytoin assay with samples from patients with renal insufficiency.
AB - Carbamazepine, phenobarbital, phenytoin, and valproic acid are commonly used antiepileptic drugs that show complicated pharmacokinetic behavior. Nonisotopic immunoassays are used routinely to monitor these drugs, and assay specificity is important to obtain accurate results. By using samples from subjects receiving each of these antiepileptic medications, competitive immunoassays for them were evaluated on an IMMULITE 2000 automated chemiluminescent analyzer (Diagnostic Products, Los Angeles, CA). Phenytoin assays were evaluated using an additional set of samples from patients with abnormal renal function. All 4 methods were linear, had imprecision of less than 10%, and compared well with other commercial immunoassays. A positive bias was observed for phenytoin measured in samples from uremic patients compared with a high-performance liquid chromatography reference method. The molar cross- reactivity of carbamazepine-10,11-epoxide was 12% in the carbamazepine assay. Phenytoin metabolites and fosphenytoin had substantial cross-reactivity in the phenytoin assay. All antiepileptic drug assays performed well and are suitable for use in monitoring patients receiving antiepileptic drug therapy. One possible exception is the phenytoin assay with samples from patients with renal insufficiency.
UR - https://academic.oup.com/ajcp/article-lookup/doi/10.1309/4502-68H7-1K1B-1JVR
UR - http://www.scopus.com/inward/record.url?scp=0036306308&partnerID=8YFLogxK
U2 - 10.1309/4502-68H7-1K1B-1JVR
DO - 10.1309/4502-68H7-1K1B-1JVR
M3 - Article
SN - 0002-9173
VL - 118
SP - 124
EP - 131
JO - American Journal of Clinical Pathology
JF - American Journal of Clinical Pathology
IS - 1
ER -